Literature DB >> 24284101

Porphyrins as urinary biomarkers for bladder cancer after 5-aminolevulinic acid (ALA) administration: the potential of photodynamic screening for tumors.

Keiji Inoue1, Urara Ota, Masahiro Ishizuka, Chiaki Kawada, Hideo Fukuhara, Taro Shuin, Ichiro Okura, Tohru Tanaka, Shun-ichiro Ogura.   

Abstract

BACKGROUND: Tumor biomarkers are commonly used for cancer screening and as indicators of treatment effects. We recently reported that urine porphyrin levels from tumor-bearing mice were elevated compared with those from normal mice after administration of 5-aminolevulinic acid (ALA). In the present study, we evaluated the use of urine samples from bladder cancer patients as tumor biomarkers.
METHODS: ALA, 1.0 g, was orally administered to 66 bladder cancer patients and 20 healthy adults. The urine concentrations of uroporphyrin I (UPI), uroporphyrin III (UPIII), coproporphyrin I (CPI), coproporphyrin III (CPIII), and total porphyrins were measured using High Performance Liquid Chromatography (HPLC) system.
RESULTS: Almost all of the urinary porphyrin concentrations from the patients with bladder cancer were higher than those from healthy adults. Moreover, 8h after ALA administration, urinary UPI and CPI showed high sensitivity (100 for UPI and CPI) and specificity (96.4 for UPI and 91.4 for CPI).
CONCLUSION: These results indicate that the presence of urinary porphyrins after administration of ALA may function as tumor biomarkers. This method represents a possible new tumor screening method called photodynamic screening (PDS) using ALA-induced porphyrins.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-Aminolevulinic acid; Coproporphyrin; Tumor biomarker; Urine; Uroporphyrin

Mesh:

Substances:

Year:  2013        PMID: 24284101     DOI: 10.1016/j.pdpdt.2013.05.002

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  10 in total

1.  Plasma protoporphyrin IX following administration of 5-aminolevulinic acid as a potential tumor marker.

Authors:  Urara Ota; Hideo Fukuhara; Masahiro Ishizuka; Fuminori Abe; Chiaki Kawada; Kenji Tamura; Tohru Tanaka; Keiji Inoue; Shun-Ichiro Ogura; Taro Shuin
Journal:  Mol Clin Oncol       Date:  2015-04-24

2.  Loss of ferrochelatase is protective against colon cancer cells: ferrochelatase a possible regulator of the long noncoding RNA H19.

Authors:  Rémi Safi; Tala Mohsen-Kanson; Georges Nemer; Batoul Dekmak; Nelly Rubeiz; Marwan El-Sabban; Dany Nassar; Assaad Eid; Ossama Abbas; Abdul-Ghani Kibbi; Mazen Kurban
Journal:  J Gastrointest Oncol       Date:  2019-10

3.  The effect of iron ion on the specificity of photodynamic therapy with 5-aminolevulinic acid.

Authors:  Maiko Hayashi; Hideo Fukuhara; Keiji Inoue; Taro Shuin; Yuichiro Hagiya; Motowo Nakajima; Tohru Tanaka; Shun-ichiro Ogura
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

4.  Oxygen Availability for Porphyrin Biosynthesis Enzymes Determines the Production of Protoporphyrin IX (PpIX) during Hypoxia.

Authors:  Shimpei Otsuka; Kentaro Matsumoto; Motowo Nakajima; Tohru Tanaka; Shun-Ichiro Ogura
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy.

Authors:  Taku Nakayama; Shimpei Otsuka; Tatsuya Kobayashi; Hodaka Okajima; Kentaro Matsumoto; Yuichiro Hagiya; Keiji Inoue; Taro Shuin; Motowo Nakajima; Tohru Tanaka; Shun-Ichiro Ogura
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

6.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas.

Authors:  Walter Stummer; Herbert Stepp; Otmar D Wiestler; Uwe Pichlmeier
Journal:  Neurosurgery       Date:  2017-08-01       Impact factor: 4.654

Review 7.  Current status of photodynamic technology for urothelial cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Atsushi Kurabayashi; Mutsuo Furihata; Kazuhiro Hanazaki; Hung Wei Lai; Shun-Ichiro Ogura
Journal:  Cancer Sci       Date:  2021-12-02       Impact factor: 6.716

Review 8.  A Recap of Heme Metabolism towards Understanding Protoporphyrin IX Selectivity in Cancer Cells.

Authors:  Martin Kiening; Norbert Lange
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

9.  The effects of the heme precursor 5-aminolevulinic acid (ALA) on REV-ERBα activation.

Authors:  Kohei Yamashita; Yuichiro Hagiya; Motowo Nakajima; Masahiro Ishizuka; Tohru Tanaka; Shun-Ichiro Ogura
Journal:  FEBS Open Bio       Date:  2014-03-26       Impact factor: 2.693

10.  Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma.

Authors:  Pamela S Jones; Anudeep Yekula; Elizabeth Lansbury; Julia L Small; Caroline Ayinon; Scott Mordecai; Fred H Hochberg; John Tigges; Bethany Delcuze; Alain Charest; Ionita Ghiran; Leonora Balaj; Bob S Carter
Journal:  EBioMedicine       Date:  2019-10-15       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.